Premium
LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma
Author(s) -
Ding Chenguang,
Han Feng,
Xiang Heli,
Xia Xinxin,
Wang Yuxiang,
Dou Meng,
Zheng Jin,
Li Yang,
Xue Wujun,
Ding Xiaoming,
Tian Puxun
Publication year - 2018
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27389
Subject(s) - clear cell renal cell carcinoma , long non coding rna , biomarker , cancer research , medicine , pathological , cell , metastasis , oncology , renal cell carcinoma , biology , cancer , gene , downregulation and upregulation , biochemistry , genetics
Colorectal neoplasia differentially expressed (CRNDE) served as an oncogenic long noncoding RNA (lncRNA) to be involved in the initialization and development of human cancers. However, the clinical significance and biological function of CRNDE in clear cell renal cell carcinoma (ccRCC) was not fully understood. In our study, we found CRNDE levels were increased in ccRCC tissue specimens and cell lines, and corrected with advanced clinical stage, large tumor size, lymph node metastasis, distant metastasis, and poor pathological grade in patients with ccRCC. Furthermore, levels of CRNDE were negatively correlated with overall survival of patients with ccRCC, and high‐expression of CRNDE was an independent poor prognostic factor for patients with ccRCC. Moreover, loss‐of‐function and gain‐of‐function approaches showed CRNDE‐enhanced ccRCC cell migration and invasion through modulating EMT‐associated genes. In conclusion, CRNDE acts as an oncogenic lncRNA in ccRCC.